Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Therapy-Related Myelodysplastic Syndrome: early-phase trial registry
1 of 5 indexed Therapy-Related Myelodysplastic Syndrome trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 1 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Therapy-Related Myelodysplastic Syndrome: 5 US clinical trials tracked, 1 recruiting.
Therapy-Related Myelodysplastic Syndrome is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Andrew E. Place, MD, running 1 of these trials.
Enrollment posture brief
Registry condition therapy-related-myelodysplastic-syndrome
OPEN 1 | RECR 20% | LATE 1 | EARLY 4 | RANK #3391 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (20% recruiting · 10 trials)
Therapy-Related Myelodysplastic Syndrome lists 1 open slots (20% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Therapy-Related Myelodysplastic Syndrome on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Therapy-Related Myelodysplastic Syndrome is recruiting below its size-band peers.
1 of 5 indexed trials (20%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Therapy-Related Myelodysplastic Syndrome research.
Andrew E. Place, MD accounts for 1 of 5 trials (20%). 5 distinct sponsors appear on at least one study for this condition label.
-
Most Therapy-Related Myelodysplastic Syndrome trials plan to enrol fewer than 100 people.
Median target enrolment is 34 among the 5 trials that report a genuine target (sentinel values excluded). 4 of those (80%) plan for fewer than 100 participants.
-
Therapy-Related Myelodysplastic Syndrome research is mostly interventional.
5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
Venetoclax Basket Trial for High Risk Hematologic Malignancies
Andrew E. Place, MD
NCT05292664
Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Orca Biosystems
NCT05316701
Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia
City of Hope Medical Center
NCT01885689
Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
M.D. Anderson Cancer Center
NCT04550442
Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic Syndrome
Uma Borate
NCT05379166
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 2 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Therapy-Related Myelodysplastic Syndrome records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Therapy-Related Myelodysplastic Syndrome trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Therapy-Related Myelodysplastic Syndrome page
5 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Therapy-Related Myelodysplastic Syndrome trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Andrew E. Place, MD sponsors the most Therapy-Related Myelodysplastic Syndrome trials on record, review their full trial history before evaluating a specific study. See Andrew E. Place, MD's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Therapy-Related Myelodysplastic Syndrome condition card totals 5 registered trials; most-linked intervention Azacitidine; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.